sg it is just discussion about the state of the industry and I find it very useful. Prana is still very much a player in the AD space from what I have seen.
Notorious is a bit extreme. I thought the Reach2HD trial was a success, and as planned, that is the program moving forward towards phase3.
Biogen had a mid stage MS trial fail in June and the price plunged about $60, now it is way past the original price on what some think is very thin AD data. Once Prana get a trial underway PBT should recover a lot of lost value IMO.
Using similar science, page-20
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.001(33.3%) |
Mkt cap ! $21.28M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $1.247K | 384.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 39 | 52935756 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 127950526 | 19 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| ATH (ASX) Chart |